Acute kidney injury in severe pneumonia associated with COVID-19
- Authors: Magomedaliev M.O.1,2, Korabelnikov D.I.1,2, Khoroshilov S.E.3
-
Affiliations:
- 1586 Military Clinical Hospital
- Moscow Medical and Social Institute named after F.P. Haaz
- Main Military Clinical Hospital named after Academician N.N. Burdenko
- Issue: Vol 24, No 3 (2022)
- Pages: 511-520
- Section: Original Study Article
- URL: https://journals.rcsi.science/1682-7392/article/view/109938
- DOI: https://doi.org/10.17816/brmma109938
- ID: 109938
Cite item
Abstract
The clinical and epidemiological features of acute kidney injury in severe and extremely severe pneumonia associated with coronavirus disease-2019 (COVID-19) are considered. An observational prospective study was conducted with the inclusion of 117 patients, including 75 men and 42 women, suffering from severe and extremely severe pneumonia associated with COVID-19, who were treated in the intensive care unit of the 1586th Military Clinical Hospital in 2020–2022. Acute kidney injury was diagnosed in 21 (17.9%) patients (stage 1 in 10, stage 2 in 4, and stage 3 in 7 patients), kidney dysfunction was recorded in 22 (8.8%) patients (serum creatinine was higher than normal, but does not reach the diagnostic criteria of Kidney Disease Improving Global Outcomes). Four patients underwent renal replacement therapy. The probability of kidney damage increases with age (the average age of the patients with acute kidney damage is 65 (58; 71) years, and those without acute kidney damage was 47.5 (41; 55) years; p = 0.0001). Compared with patients without acute kidney injury, patients with acute kidney injury scored higher on the scales NEW (p = 0.000975), SMRT-CO (p = 0.011555), and Sequential Organ Failure Assessment (p = 0.000042). Among those suffering from acute kidney injury, significantly more pronounced manifestations of systemic inflammation were determined (leukocytes, p = 0.047324; platelets, p = 0.001230; ferritin, p = 0.048614; and D-dimer, p = 0.004496). In the general cohort, the mortality rate was 22.2%, whereas a significant intergroup difference in mortality was observed, i.e., 52.4% in patients with acute kidney injury and 15.62% in those without acute kidney injury (Chi-squared criterion, 13.468; p < 0.001). Invasive artificial lung ventilation was performed in 19.66% of the patients, and a significant intergroup difference was identified, with 66.7% in patients with acute kidney injury and 9.38% in patients without acute kidney injury (Chi-squared criterion, 35.810; p < 0.001). The durations of treatment in the intensive care unit in patients with and without acute kidney injury were 9 (7; 14) and 6 (4; 10) days, respectively. After the treatment, all patients with acute kidney injury had fully recovered kidney function upon discharge. In general, acute kidney injury occurs in almost every fifth patient with severe and extremely severe pneumonia associated with COVID-19, aggravates the condition of patients, and increases mortality. The alertness of doctors regarding acute kidney injury and early diagnosis and timely nephroprotective treatment may reduce the possibility of adverse disease outcomes.
Full Text
##article.viewOnOriginalSite##About the authors
Magomedali O. Magomedaliev
1586 Military Clinical Hospital; Moscow Medical and Social Institute named after F.P. Haaz
Author for correspondence.
Email: magomedalim@mail.ru
ORCID iD: 0000-0002-0483-1050
Senior Resident
Russian Federation, Podolsk; MoscowDaniil I. Korabelnikov
1586 Military Clinical Hospital; Moscow Medical and Social Institute named after F.P. Haaz
Email: dkorabelnikov@mail.ru
ORCID iD: 0000-0002-0459-0488
SPIN-code: 7380-7790
Scopus Author ID: 7801382184
Candidate of Medical Sciences
Russian Federation, Podolsk; MoscowSergey E. Khoroshilov
Main Military Clinical Hospital named after Academician N.N. Burdenko
Email: intensive@list.ru
ORCID iD: 0000-0002-0427-8099
SPIN-code: 7071-6642
Doctor of Medical Sciences
Russian Federation, MoscowReferences
- Burki T. The origin of SARS-CoV-2. Lancet Infect Dis. 2020;20(9):1018–1019. doi: 10.1016/S1473-3099(20)30641-1
- Galanopoulos M, Gkeros F, Doukatas A, et al. COVID-19 pandemic: Pathophysiology and manifestations from the gastrointestinal tract. World J Gastroenterol. 2020;26(31):4579–4588. doi: 10.3748/wjg.v26.i31.4579
- Epidemiology Working Group for NCIP Epidemic Response C.C. for D.C. and P. Vital Surveillances: The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. China CDC Weekly. 2020;2(8):113–122. doi: 10.46234/ccdcw2020.032
- Oliveira E, Parikh A, Lopez-Ruiz A, et al. ICU outcomes and survival in patients with severe COVID-19 in the largest health care system in central Florida. PLoS One. 2021;16(3):e0249038. doi: 10.1371/journal.pone.0249038
- Phua J, Weng L, Ling L, et al. Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations. Lancet Respir Med. 2020;8(5):506–517. doi: 10.1016/S2213-2600(20)30161-2
- Wang Y, Lu X, Li Y, et al. Clinical Course and Outcomes of 344 Intensive Care Patients with COVID-19. Am J Respir Crit Care Med. 2020;201(11):1430–1434. doi: 10.1164/rccm.202003-0736LE
- Shovlin CL, Vizcaychipi MP. Implications for COVID-19 triage from the ICNARC report of 2204 COVID-19 cases managed in UK adult intensive care units. Emerg Med J. 2020;37(6):332–333. doi: 10.1136/emermed-2020-209791
- Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020;323(20):2052. doi: 10.1001/jama.2020.6775
- Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China. JAMA. 2020;323(13):1239. doi: 10.1001/jama.2020.2648
- Li X, Wang L, Yan S, et al. Clinical characteristics of 25 death cases with COVID-19: A retrospective review of medical records in a single medical center, Wuhan, China. Int J Infect Dis. 2020;94: 128–132. doi: 10.1016/j.ijid.2020.03.053
- Wiersinga WJ, Rhodes A, Cheng AC, et al. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19). JAMA. 2020;324(8):782. doi: 10.1001/jama.2020.12839
- Cheng Y, Luo R, Wang K, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020;97(5):829–838. doi: 10.1016/j.kint.2020.03.005
- Yildirim C, Ozger HS, Yasar E, et al. Early predictors of acute kidney injury in COVID-19 patients. Nephrology. 2021;26(6):513–521. doi: 10.1111/nep.13856
- Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Inter Suppl. 2012;1:1–126.
- Diao B, Wang C, Wang R, et al. Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection. Nat Commun. 2021;12(1):2506. doi: 10.1038/s41467-021-22781-1
- Chen Y-T, Shao SC, Hsu CK, et al. Incidence of acute kidney injury in COVID-19 infection: a systematic review and meta-analysis. Crit Care. 2020;24(1):346. doi: 10.1186/s13054-020-03009-y
- Lowe R, Ferrari M, Nasim-Mohi M, et al. Clinical characteristics and outcome of critically ill COVID-19 patients with acute kidney injury: a single centre cohort study. BMC Nephrol. 2021;22(1):92. doi: 10.1186/s12882-021-02296-z
- Perico L, Benigni A, Remuzzi G. Angiotensin-converting enzyme 2: from a vasoactive peptide to the gatekeeper of a global pandemic. Curr Opin Nephrol Hypertens. 2021;30(2):252–263. doi: 10.1097/MNH.0000000000000692
- Shatunova PO, Bykov AS, Svitich OA, Zverev VV. Angiotensin-converting enzyme 2. Approaches to pathogenetic therapy of COVID-19. Journal of Microbiology, Epidemiology and Immunobiology. 2020;97(4):339–345. (In Russ.) doi: 10.36233/0372-9311-2020-97-4-6
- Su H, Yang M, Wan C, et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int. 2020;98(1):219–227. doi: 10.1016/j.kint.2020.04.003
- Jones M. NEWSDIG: The National Early Warning Score Development and Implementation Group. Clin Med J. 2012;12(6): 501–503. doi: 10.7861/clinmedicine.12-6-501
- Charles PGP, Wolfe R, Whitby M, et al. SMART-COP: A Tool for Predicting the Need for Intensive Respiratory or Vasopressor Support in Community-Acquired Pneumonia. Clin Infect Dis. 2008;47(3): 375–384. doi: 10.1086/589754
- Vincent J-L, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med. 1996;22(7):707–710. doi: 10.1007/bf01709751
- Qian J-Y, Wang B, Lv L-L, Liu BC. Pathogenesis of Acute Kidney Injury in Coronavirus Disease 2019. Front Physiol. 2021;12:586589. doi: 10.3389/fphys.2021.586589
- Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus – Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061. doi: 10.1001/jama.2020.1585
- Silver SA, Beaubien-Souligny W, Shah PS, et al. The Prevalence of Acute Kidney Injury in Patients Hospitalized With COVID-19 Infection: A Systematic Review and Meta-analysis. Kidney Med. 2021;3(1):83–98.e1. doi: 10.1016/j.xkme.2020.11.008
- Chan L, Chaudhary K, Saha A, et al. AKI in Hospitalized Patients with COVID-19. J Am Soc Nephrol. 2021;32(1):151–160. doi: 10.1681/ASN.2020050615
- Kanbay M, Medetalibeyoglu A, Kanbay A, et al. Acute kidney injury in hospitalized COVID-19 patients. Int Urol Nephrol. 2022;54(5): 1097–1104. doi: 10.1007/s11255-021-02972-x
- Pode Shakked N, de Oliveira MHS, Cheruiyot I, et al. Early prediction of COVID-19-associated acute kidney injury: Are serum NGAL and serum Cystatin C levels better than serum creatinine? Clin Biochem. 2022;102:1–8. doi: 10.1016/j.clinbiochem.2022.01.006
- Pei G, Zhang Z, Peng J, et al. Renal Involvement and Early Prognosis in Patients with COVID-19 Pneumonia. J Am Soc Nephrol. 2020;31(6):1157–1165. doi: 10.1681/ASN.2020030276
- Magomedaliev MO, Korabelnikov DI, Khoroshilov SE. Acute kidney injury in patients with pneumonia. Russian Medical and Social Journal. 2019;1(1):59–73. (In Russ.) doi: 10.35571/RMSJ.2019.1.006
- Fisher M, Neugarten J, Bellin E, et al. AKI in Hospitalized Patients with and without COVID-19: A Comparison Study. J Am Soc Nephrol. 2020;31(9):2145–2157. doi: 10.1681/ASN.2020040509
Supplementary files
